Read Publication
http://dx.doi.org/10.1007/s10549-009-0644-2
The following have contributed to this page: Professor Martin Götte
This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole
- Martin Smollich, Martin Götte, Jeanett Fischgräbe, Luciana F. Macedo, Angela Brodie, Shiuan Chen, Isabel Radke, Ludwig Kiesel, Pia Wülfing
- Breast Cancer Research and Treatment, November 2009, Springer Science + Business Media
- DOI: 10.1007/s10549-009-0644-2
